Key facts
- It has raised $150.0M across 4 recorded rounds; the latest was Early Stage VC ($17.3M) in Aug 2025.
- Notable investors include General Catalyst, Khosla Ventures, New Enterprise Associates, F-Prime Capital, Nvidia — 16 tracked in total.
- CHARM Therapeutics has filed 4 Form Ds with the SEC since 2021, most recently Sep 2025 ($17.3M sold to 20 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for CHARM Therapeutics
Funding rounds
4 roundsAbout CHARM Therapeutics
Developer of a deep learning platform intended to deliver medicines of transformational efficacy for patients. The company platform delivers transformational medicines through 3D deep learning and cutting-edge drug discovery technologies, enabling doctors to treat undruggable disease targets with an advanced approach to create life-changing therapies for patients.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2021
- Employees
- 53
- Website
- charmtx.com/
- Ownership
- Privately Held (backing)
CHARM Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CHARM Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CHARM Therapeutics in its N-PORT filings yet. We sweep new filings monthly.